Aetiology of Myeloproliferative Neoplasms.
epidemiology
essential thrombocythemia
lifestyle factors
myeloproliferative neoplasms
polycythemia vera
smoking
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Jul 2020
06 Jul 2020
Historique:
received:
31
05
2020
revised:
03
07
2020
accepted:
04
07
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84, 1.03, and 0.47 per 100,000. Prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low. Patients are often concerned about why they developed an MPN and epidemiological studies enable the identification of potential causative factors. Previous work in small heterogeneous studies has identified a variety of risk factors associated with MPNs including family history of MPN, autoimmune conditions, some occupational exposures, and blood donation. At a population level, germline predisposition factors in various populations have been associated with MPNs. The pilot MOSAICC (Myeloproliferative Neoplasm: An In-depth Case-Control) study is one of the largest epidemiological studies in MPN ever carried out to date. It demonstrated the most effective methods for carrying out a significant epidemiological study in this patient group including the best way of recruiting controls, as well as how to evaluate occupational and lifestyle exposures, evaluate symptoms, and collect biological samples. Significant results linked to MPNs in the pilot study of 106 patients included smoking, obesity, and childhood socioeconomic status. The methodology is now in place for a much larger ongoing MOSAICC study which should provide further insight into the potential causes of MPNs.
Identifiants
pubmed: 32640679
pii: cancers12071810
doi: 10.3390/cancers12071810
pmc: PMC7408762
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Ann Hum Genet. 2018 Mar;82(2):114-118
pubmed: 29076129
Blood. 2016 Aug 25;128(8):1121-8
pubmed: 27365426
Transfusion. 2016 Jun;56(6 Pt 2):1622-7
pubmed: 26830533
Int J Cancer. 2020 Aug 15;147(4):948-957
pubmed: 31904114
Br J Haematol. 1998 Feb;100(2):407-10
pubmed: 9488636
Ann Hematol. 2017 Mar;96(3):373-381
pubmed: 28028559
Br J Haematol. 2016 Aug;174(3):382-96
pubmed: 27061824
J Clin Oncol. 2012 Aug 20;30(24):2995-3001
pubmed: 22802311
PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Blood. 2016 Jan 21;127(3):362-5
pubmed: 26574608
Medicina (B Aires). 1981;41(2):187-200
pubmed: 7278616
Cancer. 1996 May 15;77(10):2157-61
pubmed: 8640685
Br J Haematol. 1999 Nov;107(2):310-6
pubmed: 10583217
Br J Haematol. 2020 Apr;189(2):323-334
pubmed: 31875952
Eur J Haematol. 2017 Jan;98(1):85-93
pubmed: 27500783
Leukemia. 2014 Jun;28(6):1371-4
pubmed: 24476768
Am J Hematol. 2015 Oct;90(10):864-70
pubmed: 26113113
J Occup Med. 1986 Jul;28(7):514-6
pubmed: 3734921
Trends Mol Med. 2005 Dec;11(12):546-54
pubmed: 16271512
Haematologica. 2010 Jul;95(7):1216-20
pubmed: 20053870
Blood. 2007 Jan 1;109(1):339-42
pubmed: 16946305
Br J Cancer. 2012 Aug 21;107(5):879-87
pubmed: 22878373
Hum Genomics. 2017 Apr 20;11(1):6
pubmed: 28427458
Int J Epidemiol. 1990 Sep;19(3):505-9
pubmed: 2262240
Nat Commun. 2015 Apr 07;6:6691
pubmed: 25849990
J Intern Med. 2020 Apr;287(4):448-454
pubmed: 31927786
J Natl Cancer Inst. 1984 Jun;72(6):1223-31
pubmed: 6587144
Am J Hematol. 2019 Apr;94(4):E107-E109
pubmed: 30663086
Am J Hematol. 2014 Dec;89(12):1107-10
pubmed: 25196853
Blood. 2019 Aug 1;134(5):469-479
pubmed: 31217187
Eur J Haematol. 2014 Apr;92(4):289-97
pubmed: 24372927
Br J Cancer. 2013 Jun 11;108(11):2390-8
pubmed: 23640394
Leuk Lymphoma. 1992 Jun;7(3):251-5
pubmed: 1477653
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2011 Jul 14;118(2):401-8
pubmed: 21536863
Br J Cancer. 2009 Mar 10;100(5):822-8
pubmed: 19259097
Nat Genet. 2015 Oct;47(10):1131-40
pubmed: 26280900
Am J Hematol. 2020 Mar;95(3):295-301
pubmed: 31816122
Int J Cancer. 2014 Apr 1;134(7):1741-50
pubmed: 24114627
Am J Hematol. 2014 Jun;89(6):581-7
pubmed: 24971434
Hematol Cell Ther. 1998 Aug;40(4):159-65
pubmed: 9766920
Am J Hematol. 2019 Jan;94(1):62-73
pubmed: 30295334
Exp Hematol Oncol. 2016 May 26;5:14
pubmed: 27239389
Nat Genet. 2009 Apr;41(4):446-9
pubmed: 19287382
Hemasphere. 2020 Jan 03;4(1):e327
pubmed: 32072143
Nihon Ketsueki Gakkai Zasshi. 1974 Dec;37(6):793-5
pubmed: 4480652
J Clin Oncol. 2015 Jul 10;33(20):2288-95
pubmed: 26033810
J Clin Oncol. 2007 Dec 10;25(35):5630-5
pubmed: 17998545
Am J Hematol. 2018 Jan;93(1):100-106
pubmed: 29047144
Am J Hematol. 2012 Feb;87(2):175-82
pubmed: 22076943